Chordia Therapeutics Inc. (JP:190A) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Chordia Therapeutics Inc. has released the transcript of its earnings briefing for the fiscal year ended August 2024, aiming to enhance transparency and investor understanding. The company is actively developing cancer therapies, with its lead candidate CTX-712 undergoing Phase 1/2 clinical trials in the US.
For further insights into JP:190A stock, check out TipRanks’ Stock Analysis page.